Mitosis as an anti-cancer drug target

Chromosoma

Volumn 122, Issue 5, 2013, Pages 431-449

  Salmela, Anna Leena ^a   Kallio, Marko J ^a  

^a VTT TECHNICAL RESEARCH CENTRE OF FINLAND   (Finland)

Author keywords

Anti mitotics; Cancer; Drug development; LMW inhibitors; Mitosis

Indexed keywords

4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; 4 [[9 CHLORO 7 (2,6 DIFLUOROPHENYL) 5H PYRIMIDO[5,4 D][2]BENZAZEPIN 2 YL]AMINO]BENZOIC ACID; ALISERTIB; ALKALOID DERIVATIVE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; AURORA A INHIBITOR; AURORA B INHIBITOR; AURORA B KINASE; BARASERTIB; DANUSERTIB; ENZYME INHIBITOR; HEC1 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; ISPINESIB; KINESIN INHIBITOR; MICROTUBULE INHIBITOR; MPS1 INHIBITOR; N (3 AMINOPROPYL) N [1 (3 BENZYL 7 CHLORO 4 OXO 4H CHROMEN 2 YL) 2 METHYLPROPYL] 4 METHYLBENZAMIDE; N [4 [6 METHOXY 7 (3 MORPHOLINOPROPOXY) 4 QUINAZOLINYLAMINO]PHENYL]BENZAMIDE; PF 3814735; PLK1 INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN INHIBITOR; SP 00125; TAXANE DERIVATIVE; TOZASERTIB; UNCLASSIFIED DRUG; VOLASERTIB;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADVANCED CANCER; ANEUPLOIDY; BREAST CANCER; CANCER CHEMOTHERAPY; CELL DEATH; CELL POPULATION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COLON CANCER; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HEART DISEASE; HEMATOLOGIC MALIGNANCY; HUMAN; KAPOSI SARCOMA; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MITOSIS; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SOLID TUMOR; TARGET CELL;

ANTICARCINOGENIC AGENTS; AURORA KINASES; CELL CYCLE PROTEINS; CELL PROLIFERATION; CHROMOSOMAL PROTEINS, NON-HISTONE; HUMANS; KINESIN; MITOSIS; MOLECULAR TARGETED THERAPY; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS;

EID: 84885832802     PISSN: 00095915     EISSN: 14320886     Source Type: Journal    
DOI: 10.1007/s00412-013-0419-8     Document Type: Review

References (267)

1. Abrieu A, Magnaghi-Jaulin L, Kahana JA, Peter M, Castro A, Vigneron S, Lorca T, Cleveland DW, Labbe JC (2001) Mps1 is a kinetochore-associated kinase essential for the vertebrate mitotic checkpoint. Cell 106:83-93
2. Ahn CH, Kim YR, Kim SS, Yoo NJ, Lee SH (2009) Mutational analysis of TTK gene in gastric and colorectal cancers with microsatellite instability. Cancer Res Treat 41:224-228. doi: 10.4143/crt.2009.41.4.224
3. Aihara A, Tanaka S, Yasen M et al (2010) The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma. J Hepatol 52:63-71. doi: 10.1016/j.jhep.2009.10.013
4. Al-Janadi A, Chandana SR, Conley BA (2008) Histone deacetylation: an attractive target for cancer therapy? Drugs R D 9:369-383
5. Allan LA, Clarke PR (2007) Phosphorylation of caspase-9 by CDK1/cyclin B1 protects mitotic cells against apoptosis. Mol Cell 26:301-310. doi: 10.1016/j.molcel.2007.03.019
6. Ashar HR, James L, Gray K, Carr D, Black S, Armstrong L, Bishop WR, Kirschmeier P (2000a) Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J Biol Chem 275:30451-30457. doi: 10.1074/jbc.M003469200
7. Ashar HR, Armstrong L, James LJ, Carr DM, Gray K, Taveras A, Doll RJ, Bishop WR, Kirschmeier PT (2000b) Biological effects and mechanism of action of farnesyl transferase inhibitors. Chem Res Toxicol 13:949-952
8. Azzariti A, Bocci G, Porcelli L et al (2011) Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer. Br J Cancer 104:769-780. doi: 10.1038/bjc.2011.21
9. Bakhoum SF, Danilova OV, Kaur P, Levy NB, Compton DA (2011) Chromosomal instability substantiates poor prognosis in patients with diffuse large B-cell lymphoma. Clin Cancer Res 17:7704-7711. doi: 10.1158/1078-0432.CCR-11-2049
10. Beaupre DM, Cepero E, Obeng EA, Boise LH, Lichtenheld MG (2004) R115777 induces Ras-independent apoptosis of myeloma cells via multiple intrinsic pathways. Mol Cancer Ther 3:179-186
11. Bennett BL, Sasaki DT, Murray BW et al (2001) SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci U S A 98:13681-13686. doi: 10.1073/pnas.251194298
12. Beria I, Bossi RT, Brasca MG et al (2011) NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor. Bioorg Med Chem Lett 21:2969-2974. doi: 10.1016/j.bmcl.2011.03.054
13. Blagden SP, Molife LR, Seebaran A et al (2008) A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours. Br J Cancer 98:894-899. doi: 10.1038/sj.bjc.6604264
14. Blangy A, Lane HA, d'Herin P, Harper M, Kress M, Nigg EA (1995) Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. Cell 83:1159-1169
15. Boss DS, Witteveen PO, van der Sar J, Lolkema MP, Voest EE, Stockman PK, Ataman O, Wilson D, Das S, Schellens JH (2011) Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. Ann Oncol 22:431-437
16. Boveri T (1914) Zur Frage der Entstehung maligner tumoren. Fischer, Jena
17. Braun T, Fenaux P (2008) Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol 141:576-586. doi: 10.1111/j.1365-2141.2008.07099.x
18. Brito DA, Rieder CL (2009) The ability to survive mitosis in the presence of microtubule poisons differs significantly between human nontransformed (RPE-1) and cancer (U2OS, HeLa) cells. Cell Motil Cytoskeleton 66:437-447. doi: 10.1002/cm.20316
19. Bruserud O, Stapnes C, Ersvaer E, Gjertsen BT, Ryningen A (2007) Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cell. Curr Pharm Biotechnol 8:388-400
20. Carmena M, Earnshaw WC (2003) The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 4:842-854. doi: 10.1038/nrm1245
21. Carpinelli P, Ceruti R, Giorgini ML et al (2007) PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer. Mol Cancer Ther 6:3158-3168. doi: 10.1158/1535-7163.MCT-07-0444
22. Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z (2006) A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 38:1043-1048. doi: 10.1038/ng1861
23. Carvajal RD, Tse A, Schwartz GK (2006) Aurora kinases: new targets for cancer therapy. Clin Cancer Res 12:6869-6875. doi: 10.1158/1078-0432.CCR-06-1405
24. Chakravarty A, Shinde V, Tabernero J et al (2011) Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase. Cancer Res 71:675-685. doi: 10.1158/0008-5472.CAN- 10-1030
25. Chan KS, Koh CG, Li HY (2012) Mitosis-targeted anti-cancer therapies: where they stand. Cell Death Dis 3:e411. doi: 10.1038/cddis.2012.148
26. Cheeseman IM, Chappie JS, Wilson-Kubalek EM, Desai A (2006) The conserved KMN network constitutes the core microtubule-binding site of the kinetochore. Cell 127:983-997. doi: 10.1016/j.cell.2006.09.039
27. Chen Y, Riley DJ, Zheng L, Chen PL, Lee WH (2002) Phosphorylation of the mitotic regulator protein Hec1 by Nek2 kinase is essential for faithful chromosome segregation. J Biol Chem 277:49408-49416. doi: 10.1074/jbc.M207069200
28. Cheung CH, Coumar MS, Chang JY, Hsieh HP (2011) Aurora kinase inhibitor patents and agents in clinical testing: an update (2009-10). Expert Opin Ther Pat 21:857-884. doi: 10.1517/13543776.2011.574614
29. Chi YH, Jeang KT (2007) Aneuploidy and cancer. J Cell Biochem 102:531-538. doi: 10.1002/jcb.21484
30. Chieffi P, Cozzolino L, Kisslinger A et al (2006) Aurora B expression directly correlates with prostate cancer malignancy and influence prostate cell proliferation. Prostate 66:326-333. doi: 10.1002/pros.20345
31. Chin GM, Herbst R (2006) Induction of apoptosis by monastrol, an inhibitor of the mitotic kinesin Eg5, is independent of the spindle checkpoint. Mol Cancer Ther 5:2580-2591. doi: 10.1158/1535-7163.MCT-06-0201
32. Choi CM, Seo KW, Jang SJ, Oh YM, Shim TS, Kim WS, Lee DS, Lee SD (2009) Chromosomal instability is a risk factor for poor prognosis of adenocarcinoma of the lung: fluorescence in situ hybridization analysis of paraffin-embedded tissue from Korean patients. Lung Cancer 64:66-70. doi: 10.1016/j.lungcan.2008. 07.016
33. Chrzanowska-Wodnicka M, Burridge K (1996) Rho-stimulated contractility drives the formation of stress fibers and focal adhesions. J Cell Biol 133:1403-1415
34. Chu ML, Chavas LM, Douglas KT, Eyers PA, Tabernero L (2008) Crystal structure of the catalytic domain of the mitotic checkpoint kinase Mps1 in complex with SP600125. J Biol Chem 283:21495-21500. doi: 10.1074/jbc.M803026200
35. Chung V, Heath EI, Schelman WR, Johnson BM, Kirby LC, Lynch KM, Botbyl JD, Lampkin TA, Holen KD (2012) First-time-in-human study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory cancer. Cancer Chemother Pharmacol 69:733-741. doi: 10.1007/s00280-011-1756-z
36. Colombo R, Caldarelli M, Mennecozzi M et al (2010) Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase. Cancer Res 70:10255-10264. doi: 10.1158/0008-5472.CAN-10-2101
37. Craig RW (2002) MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis. Leukemia 16:444-454. doi: 10.1038/sj.leu.2402416
38. Crespo NC, Ohkanda J, Yen TJ, Hamilton AD, Sebti SM (2001) The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells. J Biol Chem 276:16161-16167. doi: 10.1074/jbc. M006213200
39. Crespo NC, Delarue F, Ohkanda J, Carrico D, Hamilton AD, Sebti SM (2002) The farnesyltransferase inhibitor, FTI-2153, inhibits bipolar spindle formation during mitosis independently of transformation and Ras and p53 mutation status. Cell Death Differ 9:702-709. doi: 10.1038/sj.cdd.4401023
40. Dai W, Wang Q, Liu T, Swamy M, Fang Y, Xie S, Mahmood R, Yang YM, Xu M, Rao CV (2004) Slippage of mitotic arrest and enhanced tumor development in mice with BubR1 haploinsufficiency. Cancer Res 64:440-445
41. D'Alise AM, Amabile G, Iovino M, Di Giorgio FP, Bartiromo M, Sessa F, Villa F, Musacchio A, Cortese R (2008) Reversine, a novel Aurora kinases inhibitor, inhibits colony formation of human acute myeloid leukemia cells. Mol Cancer Ther 7:1140-1149. doi: 10.1158/1535-7163.MCT-07-2051
42. Dalton WB, Yang VW (2009) Role of prolonged mitotic checkpoint activation in the formation and treatment of cancer. Future Oncol 5:1363-1370. doi: 10.2217/fon.09.118
43. Dalton WB, Nandan MO, Moore RT, Yang VW (2007) Human cancer cells commonly acquire DNA damage during mitotic arrest. Cancer Res 67:11487-11492. doi: 10.1158/0008-5472.CAN-07-5162
44. Decordier I, Cundari E, Kirsch-Volders M (2008) Survival of aneuploid, micronucleated and/or polyploid cells: crosstalk between ploidy control and apoptosis. Mutat Res 651:30-39. doi: 10.1016/j.mrgentox.2007.10.016
45. Dees EC, Infante JR, Cohen RB et al (2011) Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors. Cancer Chemother Pharmacol 67:945-954. doi: 10.1007/s00280-010-1377-y
46. Degenhardt Y, Greshock J, Laquerre S et al (2010) Sensitivity of cancer cells to Plk1 inhibitor GSK461364A is associated with loss of p53 function and chromosome instability. Mol Cancer Ther 9:2079-2089. doi: 10.1158/1535-7163.MCT- 10-0095
47. Dell'Aversana C, Lepore I, Altucci L (2012) HDAC modulation and cell death in the clinic. Exp Cell Res 318:1229-1244. doi: 10.1016/j.yexcr.2012.01. 025
48. DeLuca JG, Gall WE, Ciferri C, Cimini D, Musacchio A, Salmon ED (2006) Kinetochore microtubule dynamics and attachment stability are regulated by Hec1. Cell 127:969-982. doi: 10.1016/j.cell.2006.09.047
49. den Hollander J, Rimpi S, Doherty JR et al (2010) Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. Blood 116:1498-1505. doi: 10.1182/blood-2009-11-251074
50. Ding X, Yan F, Yao P et al (2010) Probing CENP-E function in chromosome dynamics using small molecule inhibitor syntelin. Cell Res 20:1386-1389. doi: 10.1038/cr.2010.167
51. Ditchfield C, Johnson VL, Tighe A, Ellston R, Haworth C, Johnson T, Mortlock A, Keen N, Taylor SS (2003) Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J Cell Biol 161:267-280. doi: 10.1083/jcb.200208091
52. Dorer RK, Zhong S, Tallarico JA, Wong WH, Mitchison TJ, Murray AW (2005) A small-molecule inhibitor of Mps1 blocks the spindle-checkpoint response to a lack of tension on mitotic chromosomes. Curr Biol 15:1070-1076. doi: 10.1016/j.cub.2005.05.020
53. Dreier MR, Grabovich AZ, Katusin JD, Taylor WR (2009) Short and long-term tumor cell responses to Aurora kinase inhibitors. Exp Cell Res 315:1085-1099. doi: 10.1016/j.yexcr.2009.02.008
54. Du J, Cai X, Yao J et al (2008) The mitotic checkpoint kinase NEK2A regulates kinetochore microtubule attachment stability. Oncogene 27:4107-4114. doi: 10.1038/onc.2008.34
55. Elia AE, Cantley LC, Yaffe MB (2003a) Proteomic screen finds pSer/pThr-binding domain localizing Plk1 to mitotic substrates. Science 299:1228-1231. doi: 10.1126/science.1079079
56. Elia AE, Rellos P, Haire LF, Chao JW, Ivins FJ, Hoepker K, Mohammad D, Cantley LC, Smerdon SJ, Yaffe MB (2003b) The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain. Cell 115:83-95
57. Ellis PM, Chu QS, Leighl N, Laurie SA, Fritsch H, Gaschler-Markefski B, Gyorffy S, Munzert G (2012) A phase I open-label dose-escalation study of intravenous BI 2536 together with pemetrexed in previously treated patients with non-small-cell lung cancer. Clin Lung Cancer 14:19-27. doi: 10.1016/j.cllc.2012.04.003
58. Eot-Houllier G, Fulcrand G, Magnaghi-Jaulin L, Jaulin C (2009) Histone deacetylase inhibitors and genomic instability. Cancer Lett 274:169-176. doi: 10.1016/j.canlet.2008.06.005
59. Espeut J, Gaussen A, Bieling P, Morin V, Prieto S, Fesquet D, Surrey T, Abrieu A (2008) Phosphorylation relieves autoinhibition of the kinetochore motor Cenp-E. Mol Cell 29:637-643. doi: 10.1016/j.molcel.2008.01.004
60. Evans RP, Naber C, Steffler T, Checkland T, Maxwell CA, Keats JJ, Belch AR, Pilarski LM, Lai R, Reiman T (2008) The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma. Br J Haematol 140:295-302. doi: 10.1111/j.1365-2141.2007.06913.x
61. Ewart-Toland A, Briassouli P, de Koning JP et al (2003) Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. Nat Genet 34:403-412. doi: 10.1038/ng1220
62. Fancelli D, Moll J, Varasi M et al (2006) 1,4,5,6-Tetrahydropyrrolo[3,4- c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile. J Med Chem 49:7247-7251. doi: 10.1021/jm060897w
63. Fraizer GC, Diaz MF, Lee IL, Grossman HB, Sen S (2004) Aurora-A/STK15/BTAK enhances chromosomal instability in bladder cancer cells. Int J Oncol 25:1631-1639
64. Gabrielli B, Warrener R, Burgess A, Beamish H (2004) Defining the chemotherapeutic targets of histone deacetylase inhibitors. Ann N Y Acad Sci 1030:627-635. doi: 10.1196/annals.1329.073
65. Ganem NJ, Pellman D (2007) Limiting the proliferation of polyploid cells. Cell 131:437-440. doi: 10.1016/j.cell.2007.10.024
66. Gao F, Ponte JF, Levy M et al (2009) hBub1 negatively regulates p53 mediated early cell death upon mitotic checkpoint activation. Cancer Biol Ther 8:548-556
67. Garcia-Saez I, Blot D, Kahn R, Kozielski F (2004) Crystallization and preliminary crystallographic analysis of the motor domain of human kinetochore-associated protein CENP-E using an automated crystallization procedure. Acta Crystallogr D: Biol Crystallogr 60:1158-1160. doi: 10.1107/S0907444904009564
68. Gascoigne KE, Taylor SS (2008) Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell 14:111-122. doi: 10.1016/j.ccr.2008.07.002
69. Gascoigne KE, Taylor SS (2009) How do anti-mitotic drugs kill cancer cells? J Cell Sci 122:2579-2585. doi: 10.1242/jcs.039719
70. Giles FJ, Cortes J, Jones D, Bergstrom D, Kantarjian H, Freedman SJ (2007) MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 109:500-502. doi: 10.1182/blood-2006-05-025049
71. Gilmartin AG, Bleam MR, Richter MC et al (2009) Distinct concentration-dependent effects of the Polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis. Cancer Res 69:6969-6977. doi: 10.1158/0008-5472.CAN-09-0945
72. Gizatullin F, Yao Y, Kung V, Harding MW, Loda M, Shapiro GI (2006) The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function. Cancer Res 66:7668-7677. doi: 10.1158/0008-5472.CAN-05-3353
73. Gontarewicz A, Balabanov S, Keller G et al (2008) Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood 111:4355-4364. doi: 10.1182/blood-2007-09-113175
74. Gordon DJ, Resio B, Pellman D (2012) Causes and consequences of aneuploidy in cancer. Nat Rev Genet 13:189-203. doi: 10.1038/nrg3123
75. Grant S (2008) Is the focus moving toward a combination of targeted drugs? Best Pract Res Clin Haematol 21:629-637. doi: 10.1016/j.beha.2008.08.003
76. Guo Y, Kim C, Ahmad S, Zhang J, Mao Y (2012) CENP-E-dependent BubR1 autophosphorylation enhances chromosome alignment and the mitotic checkpoint. J Cell Biol 198:205-217. doi: 10.1083/jcb.201202152
77. Gurzov EN, Izquierdo M (2006) RNA interference against Hec1 inhibits tumor growth in vivo. Gene Ther 13:1-7. doi: 10.1038/sj.gt.3302595
78. Hanisch A, Wehner A, Nigg EA, Sillje HH (2006) Different Plk1 functions show distinct dependencies on Polo-Box domain-mediated targeting. Mol Biol Cell 17:448-459. doi: 10.1091/mbc.E05-08-0801
79. Hanks S, Coleman K, Reid S et al (2004) Constitutional aneuploidy and cancer predisposition caused by biallelic mutations in BUB1B. Nat Genet 36:1159-1161. doi: 10.1038/ng1449
80. Hardy PA, Zacharias H (2005) Reappraisal of the Hansemann-Boveri hypothesis on the origin of tumors. Cell Biol Int 29:983-992. doi: 10.1016/j.cellbi.2005.10.001
81. Harley ME, Allan LA, Sanderson HS, Clarke PR (2010) Phosphorylation of Mcl-1 by CDK1-cyclin B1 initiates its Cdc20-dependent destruction during mitotic arrest. EMBO J 29:2407-2420. doi: 10.1038/emboj.2010.112
82. Harousseau JL (2007) Farnesyltransferase inihibitors in hematologic malignancies. Blood Rev 21:173-182. doi: 10.1016/j.blre.2006.12.001
83. Harrington EA, Bebbington D, Moore J et al (2004) VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 10:262-267. doi: 10.1038/nm1003
84. Hasle H, Clemmensen IH, Mikkelsen M (2000) Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet 355:165-169. doi: 10.1016/S0140-6736(99)05264-2
85. Hauf S, Cole RW, LaTerra S, Zimmer C, Schnapp G, Walter R, Heckel A, van Meel J, Rieder CL, Peters JM (2003) The small molecule hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J Cell Biol 161:281-294. doi: 10.1083/jcb.200208092
86. Heilig CE, Loffler H, Mahlknecht U, Janssen JW, Ho AD, Jauch A, Kramer A (2010) Chromosomal instability correlates with poor outcome in patients with myelodysplastic syndromes irrespectively of the cytogenetic risk group. J Cell Mol Med 14:895-902. doi: 10.1111/j.1582-4934.2009.00905.x
87. Henderson MC, Shaw YJ, Wang H, Han H, Hurley LH, Flynn G, Dorr RT, Von Hoff DD (2009) UA62784, a novel inhibitor of centromere protein E kinesin-like protein. Mol Cancer Ther 8:36-44. doi: 10.1158/1535-7163.MCT-08-0789
88. Hewitt L, Tighe A, Santaguida S, White AM, Jones CD, Musacchio A, Green S, Taylor SS (2010) Sustained Mps1 activity is required in mitosis to recruit O-Mad2 to the Mad1-C-Mad2 core complex. J Cell Biol 190:25-34. doi: 10.1083/jcb.201002133
89. Hoar K, Chakravarty A, Rabino C, Wysong D, Bowman D, Roy N, Ecsedy JA (2007) MLN8054, a small-molecule inhibitor of Aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy. Mol Cell Biol 27:4513-4525. doi: 10.1128/MCB.02364-06
90. Holen KD, Belani CP, Wilding G et al (2011) A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose. Cancer Chemother Pharmacol 67:447-454. doi: 10.1007/s00280-010-1346-5
91. Holland AJ, Cleveland DW (2012) Losing balance: the origin and impact of aneuploidy in cancer. EMBO Rep 13:501-514. doi: 10.1038/embor.2012.55
92. How J, Yee K (2012) ENMD-2076 for hematological malignancies. Expert Opin Investig Drugs 21:717-732. doi: 10.1517/13543784.2012.668882
93. Huang H, Hittle J, Zappacosta F, Annan RS, Hershko A, Yen TJ (2008) Phosphorylation sites in BubR1 that regulate kinetochore attachment, tension, and mitotic exit. J Cell Biol 183:667-680. doi: 10.1083/jcb.200805163
94. Huang HC, Shi J, Orth JD, Mitchison TJ (2009a) Evidence that mitotic exit is a better cancer therapeutic target than spindle assembly. Cancer Cell 16:347-358. doi: 10.1016/j.ccr.2009.08.020
95. Huang YF, Chang MD, Shieh SY (2009b) TTK/hMps1 mediates the p53-dependent postmitotic checkpoint by phosphorylating p53 at Thr18. Mol Cell Biol 29:2935-2944. doi: 10.1128/MCB.01837-08
96. Hussein D, Taylor SS (2002) Farnesylation of Cenp-F is required for G2/M progression and degradation after mitosis. J Cell Sci 115:3403-3414
97. Huszar D, Theoclitou ME, Skolnik J, Herbst R (2009) Kinesin motor proteins as targets for cancer therapy. Cancer Metastasis Rev. doi: 10.1007/s10555-009-9185-8
98. Ikui AE, Yang CP, Matsumoto T, Horwitz SB (2005) Low concentrations of taxol cause mitotic delay followed by premature dissociation of p55CDC from Mad2 and BubR1 and abrogation of the spindle checkpoint, leading to aneuploidy. Cell Cycle 4:1385-1388
99. Inuzuka H, Shaik S, Onoyama I et al (2011) SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature 471:104-109. doi: 10.1038/nature09732
100. Iwanaga Y, Chi YH, Miyazato A, Sheleg S, Haller K, Peloponese JM Jr, Li Y, Ward JM, Benezra R, Jeang KT (2007) Heterozygous deletion of mitotic arrest-deficient protein 1 (MAD1) increases the incidence of tumors in mice. Cancer Res 67:160-166. doi: 10.1158/0008-5472.CAN-06-3326
101. Jallepalli PV, Lengauer C (2001) Chromosome segregation and cancer: cutting through the mystery. Nat Rev Cancer 1:109-117. doi: 10.1038/35101065
102. Jani JP, Arcari J, Bernardo V et al (2010) PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapy. Mol Cancer Ther 9:883-894. doi: 10.1158/1535-7163.MCT-09-0915
103. Janssen A, Medema RH (2011) Mitosis as an anti-cancer target. Oncogene 30:2799-2809. doi: 10.1038/onc.2011.30
104. Janssen A, Kops GJ, Medema RH (2009) Elevating the frequency of chromosome mis-segregation as a strategy to kill tumor cells. Proc Natl Acad Sci U S A 106:19108-19113. doi: 10.1073/pnas.0904343106
105. Jeganathan K, Malureanu L, Baker DJ, Abraham SC, van Deursen JM (2007) Bub1 mediates cell death in response to chromosome missegregation and acts to suppress spontaneous tumorigenesis. J Cell Biol 179:255-267. doi: 10.1083/jcb.200706015
106. Jelluma N, Brenkman AB, McLeod I, Yates JR 3rd, Cleveland DW, Medema RH, Kops GJ (2008a) Chromosomal instability by inefficient Mps1 auto-activation due to a weakened mitotic checkpoint and lagging chromosomes. PLoS One 3:e2415. doi: 10.1371/journal.pone.0002415
107. Jelluma N, Brenkman AB, van den Broek NJ, Cruijsen CW, van Osch MH, Lens SM, Medema RH, Kops GJ (2008b) Mps1 phosphorylates Borealin to control Aurora B activity and chromosome alignment. Cell 132:233-246. doi: 10.1016/j.cell.2007. 11.046
108. Jeng YM, Peng SY, Lin CY, Hsu HC (2004) Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res 10:2065-2071
109. Jiang Y, Zhang Y, Lees E, Seghezzi W (2003) AuroraA overexpression overrides the mitotic spindle checkpoint triggered by nocodazole, a microtubule destabilizer. Oncogene 22:8293-8301. doi: 10.1038/sj.onc.1206873
110. Jones SF, Plummer ER, Burris HA, Razak AR, Meluch A, Bowen CJ, Williams DH, Hodge JP, Dar MM, Calvert AH (2006) Phase I study of ispinesib in combination with carboplatin in patients with advanced solid tumors. J Clin Oncol 24(18 Supplement):2027, ASCO Meeting Abstracts 5/17/2013 2013
111. Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4:253-265. doi: 10.1038/nrc1317
112. Kaestner P, Bastians H (2010) Mitotic drug targets. J Cell Biochem 111:258-265. doi: 10.1002/jcb.22721
113. Kaestner P, Stolz A, Bastians H (2009) Determinants for the efficiency of anticancer drugs targeting either Aurora-A or Aurora-B kinases in human colon carcinoma cells. Mol Cancer Ther 8:2046-2056. doi: 10.1158/1535-7163.MCT-09-0323
114. Kanda A, Kawai H, Suto S, Kitajima S, Sato S, Takata T, Tatsuka M (2005) Aurora-B/AIM-1 kinase activity is involved in Ras-mediated cell transformation. Oncogene 24:7266-7272. doi: 10.1038/sj.onc.1208884
115. Kapoor TM, Lampson MA, Hergert P, Cameron L, Cimini D, Salmon ED, McEwen BF, Khodjakov A (2006) Chromosomes can congress to the metaphase plate before biorientation. Science 311:388-391. doi: 10.1126/science.1122142
116. Katayama H, Ota T, Jisaki F, Ueda Y, Tanaka T, Odashima S, Suzuki F, Terada Y, Tatsuka M (1999) Mitotic kinase expression and colorectal cancer progression. J Natl Cancer Inst 91:1160-1162
117. Keen N, Taylor S (2009) Mitotic drivers-inhibitors of the Aurora B kinase. Cancer Metastasis Rev. doi: 10.1007/s10555-009-9184-9
118. Kim Y, Holland AJ, Lan W, Cleveland DW (2010) Aurora kinases and protein phosphatase 1 mediate chromosome congression through regulation of CENP-E. Cell 142:444-455. doi: 10.1016/j.cell.2010.06.039
119. King RW (2008) When 2 + 2 = 5: the origins and fates of aneuploid and tetraploid cells. Biochim Biophys Acta 1786:4-14. doi: 10.1016/j.bbcan.2008.07. 007
120. Kohl NE, Mosser SD, deSolms SJ, Giuliani EA, Pompliano DL, Graham SL, Smith RL, Scolnick EM, Oliff A, Gibbs JB (1993) Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 260:1934-1937
121. Kollareddy M, Zheleva D, Dzubak P, Brahmkshatriya PS, Lepsik M, Hajduch M (2012) Aurora kinase inhibitors: progress towards the clinic. Invest New Drugs. doi: 10.1007/s10637-012-9798-6
122. Komlodi-Pasztor E, Sackett DL, Fojo AT (2012) Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationale. Clin Cancer Res 18:51-63. doi: 10.1158/1078-0432.CCR-11- 0999
123. Kops GJ, Foltz DR, Cleveland DW (2004) Lethality to human cancer cells through massive chromosome loss by inhibition of the mitotic checkpoint. Proc Natl Acad Sci U S A 101:8699-8704. doi: 10.1073/pnas.0401142101
124. Kops GJ, Weaver BA, Cleveland DW (2005) On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer 5:773-785. doi: 10.1038/nrc1714
125. Kramer A, Maier B, Bartek J (2011) Centrosome clustering and chromosomal (in)stability: a matter of life and death. Mol Oncol 5:324-335. doi: 10.1016/j.molonc.2011.05.003
126. Kronenwett U, Huwendiek S, Ostring C, Portwood N, Roblick UJ, Pawitan Y, Alaiya A, Sennerstam R, Zetterberg A, Auer G (2004) Improved grading of breast adenocarcinomas based on genomic instability. Cancer Res 64:904-909
127. Kurai M, Shiozawa T, Shih HC, Miyamoto T, Feng YZ, Kashima H, Suzuki A, Konishi I (2005) Expression of Aurora kinases A and B in normal, hyperplastic, and malignant human endometrium: Aurora B as a predictor for poor prognosis in endometrial carcinoma. Hum Pathol 36:1281-1288. doi: 10.1016/j.humpath.2005.09. 014
128. Kwiatkowski N, Jelluma N, Filippakopoulos P et al (2010) Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function. Nat Chem Biol 6:359-368. doi: 10.1038/nchembio.345
129. Kwiatkowski N, Deng X, Wang J, Tan L, Villa F, Santaguida S, Huang HC, Mitchison T, Musacchio A, Gray N (2012) Selective aurora kinase inhibitors identified using a taxol-induced checkpoint sensitivity screen. ACS Chem Biol 7:185-196. doi: 10.1021/cb200305u
130. Lan W, Cleveland DW (2010) A chemical tool box defines mitotic and interphase roles for Mps1 kinase. J Cell Biol 190:21-24. doi: 10.1083/jcb.201006080
131. Lansing TJ, McConnell RT, Duckett DR et al (2007) In vitro biological activity of a novel small-molecule inhibitor of Polo-like kinase 1. Mol Cancer Ther 6:450-459. doi: 10.1158/1535-7163.MCT-06-0543
132. Lapenna S, Giordano A (2009) Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 8:547-566. doi: 10.1038/nrd2907
133. Laster SM, Mackenzie JM Jr (1996) Bleb formation and F-actin distribution during mitosis and tumor necrosis factor-induced apoptosis. Microsc Res Tech 34:272-280
134. Lee KS, Grenfell TZ, Yarm FR, Erikson RL (1998) Mutation of the polo-box disrupts localization and mitotic functions of the mammalian polo kinase Plk. Proc Natl Acad Sci U S A 95:9301-9306
135. Lee RT, Beekman KE, Hussain M, Davis NB, Clark JI, Thomas SP, Nichols KF, Stadler WM (2008) A University of Chicago consortium phase II trial of SB-715992 in advanced renal cell cancer. Clin Genitourin Cancer 6:21-24. doi: 10.3816/CGC.2008.n.003
136. Lee AJ, Endesfelder D, Rowan AJ et al (2011) Chromosomal instability confers intrinsic multidrug resistance. Cancer Res 71:1858-1870. doi: 10.1158/0008-5472.CAN-10-3604
137. LeRoy PJ, Hunter JJ, Hoar KM, Burke KE, Shinde V, Ruan J, Bowman D, Galvin K, Ecsedy JA (2007) Localization of human TACC3 to mitotic spindles is mediated by phosphorylation on Ser558 by Aurora A: a novel pharmacodynamic method for measuring Aurora A activity. Cancer Res 67:5362-5370. doi: 10.1158/0008-5472.CAN-07-0122
138. Li T, Sparano JA (2008) Farnesyl transferase inhibitors. Cancer Invest 26:653-661. doi: 10.1080/07357900801971016
139. Li L, Yang L, Scudiero DA, Miller SA, Yu ZX, Stukenberg PT, Shoemaker RH, Kotin RM (2007) Development of recombinant adeno-associated virus vectors carrying small interfering RNA (shHec1)-mediated depletion of kinetochore Hec1 protein in tumor cells. Gene Ther 14:814-827. doi: 10.1038/sj.gt.3302933
140. Lin YT, Chen Y, Wu G, Lee WH (2006) Hec1 sequentially recruits Zwint-1 and ZW10 to kinetochores for faithful chromosome segregation and spindle checkpoint control. Oncogene 25:6901-6914. doi: 10.1038/sj.onc.1209687
141. Liu X, Erikson RL (2003) Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci U S A 100:5789-5794. doi: 10.1073/pnas.1031523100
142. Lowenberg B, Muus P, Ossenkoppele G et al (2011) Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. Blood 118:6030-6036. doi: 10.1182/blood-2011-07-366930
143. Luo L, Parrish CA, Nevins N et al (2007) ATP-competitive inhibitors of the mitotic kinesin KSP that function via an allosteric mechanism. Nat Chem Biol 3:722-726. doi: 10.1038/nchembio.2007.34
144. Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, Westbrook TF, Wong KK, Elledge SJ (2009) A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137:835-848. doi: 10.1016/j.cell.2009.05.006
145. Magnaghi-Jaulin L, Eot-Houllier G, Fulcrand G, Jaulin C (2007) Histone deacetylase inhibitors induce premature sister chromatid separation and override the mitotic spindle assembly checkpoint. Cancer Res 67:6360-6367. doi: 10.1158/0008-5472.CAN-06-3012
146. Maliga Z, Mitchison TJ (2006) Small-molecule and mutational analysis of allosteric Eg5 inhibition by monastrol. BMC Chem Biol 6:2. doi: 10.1186/1472-6769-6-2
147. Manchado E, Guillamot M, Malumbres M (2012) Killing cells by targeting mitosis. Cell Death Differ 19:369-377. doi: 10.1038/cdd.2011.197
148. Manfredi MG, Ecsedy JA, Meetze KA et al (2007) Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci U S A 104:4106-4111. doi: 10.1073/pnas.0608798104
149. Margolis RL, Lohez OD, Andreassen PR (2003) G1 tetraploidy checkpoint and the suppression of tumorigenesis. J Cell Biochem 88:673-683. doi: 10.1002/jcb.10411
150. Marumoto T, Zhang D, Saya H (2005) Aurora-A - a guardian of poles. Nat Rev Cancer 5:42-50. doi: 10.1038/nrc1526
151. Masuda A, Maeno K, Nakagawa T, Saito H, Takahashi T (2003) Association between mitotic spindle checkpoint impairment and susceptibility to the induction of apoptosis by anti-microtubule agents in human lung cancers. Am J Pathol 163:1109-1116. doi: 10.1016/S0002-9440(10)63470-0
152. Matson DR, Stukenberg PT (2011) Spindle poisons and cell fate: a tale of two pathways. Mol Interv 11:141-150. doi: 10.1124/mi.11.2.12
153. Matulonis UA, Sharma S, Ghamande S et al (2012) Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Gynecol Oncol 127:63-69. doi: 10.1016/j.ygyno.2012.06.040
154. Matulonis UA, Lee J, Lasonde B et al (2013) ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer. Eur J Cancer 49:121-131. doi: 10.1016/j.ejca.2012.07. 020
155. McCleland ML, Gardner RD, Kallio MJ, Daum JR, Gorbsky GJ, Burke DJ, Stukenberg PT (2003) The highly conserved Ndc80 complex is required for kinetochore assembly, chromosome congression, and spindle checkpoint activity. Genes Dev 17:101-114. doi: 10.1101/gad.1040903
156. McInnes C, Wyatt MD (2011) PLK1 as an oncology target: current status and future potential. Drug Discov Today 16:619-625. doi: 10.1016/j.drudis.2011.05. 002
157. McInnes C, Mezna M, Fischer PM (2005) Progress in the discovery of Polo-like kinase inhibitors. Curr Top Med Chem 5:181-197
158. McLaughlin J, Markovtsov V, Li H et al (2010) Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen. J Cancer Res Clin Oncol 136:99-113. doi: 10.1007/s00432-009-0641-1
159. Meraldi P, Honda R, Nigg EA (2002) Aurora-A overexpression reveals tetraploidization as a major route to centrosome amplification in p53-/- cells. EMBO J 21:483-492
160. Mikule K, Delaval B, Kaldis P, Jurcyzk A, Hergert P, Doxsey S (2007) Loss of centrosome integrity induces p38-p53-p21-dependent G1-S arrest. Nat Cell Biol 9:160-170
161. Minton SE, LoRusso P, Lockhart AC, Saif M, Krishnamurthi SS, Pickett-Gies CA, Wang Y, Guan S, Roben E, Stein MN (2010) A phase I study of MK-5108, an oral aurora A kinase inhibitor, in both monotherapy and in combination with docetaxel in patients with advanced solid tumors. J Clin Oncol 28(15):e13026, ASCO Meeting Abstracts 5/17/2013 2013
162. Mitchison TJ (2012) The proliferation rate paradox in antimitotic chemotherapy. Mol Biol Cell 23:1-6. doi: 10.1091/mbc.E10-04-0335
163. Miyoshi Y, Iwao K, Egawa C, Noguchi S (2001) Association of centrosomal kinase STK15/BTAK mRNA expression with chromosomal instability in human breast cancers. Int J Cancer 92:370-373
164. Mortlock AA, Foote KM, Heron NM et al (2007) Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase. J Med Chem 50:2213-2224. doi: 10.1021/jm061335f
165. Mross K, Frost A, Steinbild S, Hedbom S, Rentschler J, Kaiser R, Rouyrre N, Trommeshauser D, Hoesl CE, Munzert G (2008) Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J Clin Oncol 26:5511-5517. doi: 10.1200/JCO.2008.16.1547
166. Musacchio A, Salmon ED (2007) The spindle-assembly checkpoint in space and time. Nat Rev Mol Cell Biol 8:379-393. doi: 10.1038/nrm2163
167. Nair J, Keen N, Schwartz G (2004) A novel aurora B kinase inhibitor with potent anticancer activity either as a single agent or in combination with chemotherapy [abstract 9568]. Proc Am Soc Clin Oncol 23:848
168. Nair JS, Ho AL, Tse AN, Coward J, Cheema H, Ambrosini G, Keen N, Schwartz GK (2009) Aurora B kinase regulates the postmitotic endoreduplication checkpoint via phosphorylation of the retinoblastoma protein at serine 780. Mol Biol Cell 20:2218-2228. doi: 10.1091/mbc.E08-08-0885
169. Noh EJ, Lim DS, Jeong G, Lee JS (2009) An HDAC inhibitor, trichostatin A, induces a delay at G2/M transition, slippage of spindle checkpoint, and cell death in a transcription-dependent manner. Biochem Biophys Res Commun 378:326-331. doi: 10.1016/j.bbrc.2008.11.057
170. Olmos D, Barker D, Sharma R et al (2011) Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies. Clin Cancer Res 17:3420-3430. doi: 10.1158/1078-0432.CCR- 10-2946
171. Ota T, Suto S, Katayama H, Han ZB, Suzuki F, Maeda M, Tanino M, Terada Y, Tatsuka M (2002) Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora-B overexpression contributes to chromosome number instability. Cancer Res 62:5168-5177
172. Panda D, Jordan MA, Chu KC, Wilson L (1996) Differential effects of vinblastine on polymerization and dynamics at opposite microtubule ends. J Biol Chem 271:29807-29812
173. Pandha H, Protheroe A, Wylie J, Parker C, Chambers J, Bell S, Munzert G (2008) An open label phase II trial of BI 2536, a novel Plk1 inhibitor, in patients with metastatic hormone refractory prostate cancer (HRPC). J Clin Oncol (26):(May 20 suppl;abstr 14547)
174. Paoletti A, Giocanti N, Favaudon V, Bornens M (1997) Pulse treatment of interphasic HeLa cells with nanomolar doses of docetaxel affects centrosome organization and leads to catastrophic exit of mitosis. J Cell Sci 110(Pt 19):2403-2415
175. Park JH, Jong HS, Kim SG, Jung Y, Lee KW, Lee JH, Kim DK, Bang YJ, Kim TY (2008) Inhibitors of histone deacetylases induce tumor-selective cytotoxicity through modulating Aurora-A kinase. J Mol Med (Berl) 86:117-128. doi: 10.1007/s00109-007-0260-8
176. Parrish CA, Adams ND, Auger KR et al (2007) Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem 50:4939-4952. doi: 10.1021/jm070435y
177. Portugal J, Mansilla S, Bataller M (2010) Mechanisms of drug-induced mitotic catastrophe in cancer cells. Curr Pharm Des 16:69-78
178. Purcell JW, Davis J, Reddy M et al (2010) Activity of the kinesin spindle protein inhibitor ispinesib (SB-715992) in models of breast cancer. Clin Cancer Res 16:566-576. doi: 10.1158/1078-0432.CCR-09-1498
179. Putkey FR, Cramer T, Morphew MK, Silk AD, Johnson RS, McIntosh JR, Cleveland DW (2002) Unstable kinetochore-microtubule capture and chromosomal instability following deletion of CENP-E. Dev Cell 3:351-365
180. Qiu XL, Li G, Wu G, Zhu J, Zhou L, Chen PL, Chamberlin AR, Lee WH (2009) Synthesis and biological evaluation of a series of novel inhibitor of Nek2/Hec1 analogues. J Med Chem 52:1757-1767. doi: 10.1021/jm8015969
181. Rath O, Kozielski F (2012) Kinesins and cancer. Nat Rev Cancer 12:527-539. doi: 10.1038/nrc3310
182. Reindl W, Yuan J, Kramer A, Strebhardt K, Berg T (2008) Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions. Chem Biol 15:459-466. doi: 10.1016/j.chembiol.2008.03.013
183. Rickert KW, Schaber M, Torrent M et al (2008) Discovery and biochemical characterization of selective ATP competitive inhibitors of the human mitotic kinesin KSP. Arch Biochem Biophys 469:220-231. doi: 10.1016/j.abb.2007.10.016
184. Rieder CL, Maiato H (2004) Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. Dev Cell 7:637-651. doi: 10.1016/j.devcel.2004.09.002
185. Rudolph J (2007) Inhibiting transient protein-protein interactions: lessons from the Cdc25 protein tyrosine phosphatases. Nat Rev Cancer 7:202-211. doi: 10.1038/nrc2087
186. Rudolph D, Steegmaier M, Hoffmann M, Grauert M, Baum A, Quant J, Haslinger C, Garin-Chesa P, Adolf GR (2009) BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin Cancer Res 15:3094-3102. doi: 10.1158/1078-0432.CCR-08-2445
187. Salmela AL, Pouwels J, Varis A, Kukkonen AM, Toivonen P, Halonen PK, Perala M, Kallioniemi O, Gorbsky GJ, Kallio MJ (2009) Dietary flavonoid fisetin induces a forced exit from mitosis by targeting the mitotic spindle checkpoint. Carcinogenesis 30:1032-1040. doi: 10.1093/carcin/bgp101
188. Salmela AL, Pouwels J, Maki-Jouppila J, Kohonen P, Toivonen P, Kallio L, Kallio M (2012) Novel pyrimidine-2,4-diamine derivative suppresses the cell viability and spindle assembly checkpoint activity by targeting Aurora kinases. Carcinogenesis. doi: 10.1093/carcin/bgs339
189. Santaguida S, Tighe A, D'Alise AM, Taylor SS, Musacchio A (2010) Dissecting the role of MPS1 in chromosome biorientation and the spindle checkpoint through the small molecule inhibitor reversine. J Cell Biol 190:73-87. doi: 10.1083/jcb.201001036
190. Schafer-Hales K, Iaconelli J, Snyder JP, Prussia A, Nettles JH, El-Naggar A, Khuri FR, Giannakakou P, Marcus AI (2007) Farnesyl transferase inhibitors impair chromosomal maintenance in cell lines and human tumors by compromising CENP-E and CENP-F function. Mol Cancer Ther 6:1317-1328. doi: 10.1158/1535-7163.MCT-06-0703
191. Schmidt M, Bastians H (2007) Mitotic drug targets and the development of novel anti-mitotic anticancer drugs. Drug Resist Updat 10:162-181. doi: 10.1016/j.drup.2007.06.003
192. Schmidt M, Budirahardja Y, Klompmaker R, Medema RH (2005) Ablation of the spindle assembly checkpoint by a compound targeting Mps1. EMBO Rep 6:866-872. doi: 10.1038/sj.embor.7400483
193. Schoffski P, Awada A, Dumez H, Gil T, Bartholomeus S, Wolter P, Taton M, Fritsch H, Glomb P, Munzert G (2012) A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. Eur J Cancer 48:179-186. doi: 10.1016/j.ejca.2011.11.001
194. Sebastian M, Reck M, Waller CF et al (2010) The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial. J Thorac Oncol 5:1060-1067. doi: 10.1097/JTO.0b013e3181d95dd4
195. Seong YS, Kamijo K, Lee JS, Fernandez E, Kuriyama R, Miki T, Lee KS (2002) A spindle checkpoint arrest and a cytokinesis failure by the dominant-negative polo-box domain of Plk1 in U-2 OS cells. J Biol Chem 277:32282-32293. doi: 10.1074/jbc.M202602200
196. Shi J, Orth JD, Mitchison T (2008) Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5. Cancer Res 68:3269-3276. doi: 10.1158/0008-5472.CAN-07-6699
197. Shih IM, Zhou W, Goodman SN, Lengauer C, Kinzler KW, Vogelstein B (2001) Evidence that genetic instability occurs at an early stage of colorectal tumorigenesis. Cancer Res 61:818-822
198. Shimomura T, Hasako S, Nakatsuru Y et al (2010) MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel. Mol Cancer Ther 9:157-166. doi: 10.1158/1535-7163. MCT-09-0609
199. Smith MR, Wilson ML, Hamanaka R, Chase D, Kung H, Longo DL, Ferris DK (1997) Malignant transformation of mammalian cells initiated by constitutive expression of the Polo-like kinase. Biochem Biophys Res Commun 234:397-405
200. Smith SL, Bowers NL, Betticher DC, Gautschi O, Ratschiller D, Hoban PR, Booton R, Santibanez-Koref MF, Heighway J (2005) Overexpression of aurora B kinase (AURKB) in primary non-small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instability. Br J Cancer 93:719-729. doi: 10.1038/sj.bjc.6602779
201. Song SY, Meszoely IM, Coffey RJ, Pietenpol JA, Leach SD (2000) K-Ras-independent effects of the farnesyl transferase inhibitor L-744,832 on cyclin B1/Cdc2 kinase activity, G2/M cell cycle progression and apoptosis in human pancreatic ductal adenocarcinoma cells. Neoplasia 2:261-272
202. Sorrentino R, Libertini S, Pallante PL et al (2005) Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation. J Clin Endocrinol Metab 90:928-935. doi: 10.1210/jc.2004-1518
203. Sotillo R, Schvartzman JM, Socci ND, Benezra R (2010) Mad2-induced chromosome instability leads to lung tumour relapse after oncogene withdrawal. Nature 464:436-440. doi: 10.1038/nature08803
204. Souid AK, Dubowy RL, Ingle AM, Conlan MG, Sun J, Blaney SM, Adamson PC (2010) A pediatric phase I trial and pharmacokinetic study of ispinesib: a Children's Oncology Group Phase I Consortium study. Pediatr Blood Cancer 55:1323-1328. doi: 10.1002/pbc.22609
205. Spankuch B, Heim S, Kurunci-Csacsko E, Lindenau C, Yuan J, Kaufmann M, Strebhardt K (2006) Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo. Cancer Res 66:5836-5846. doi: 10.1158/0008-5472.CAN-06-0343
206. Spankuch B, Kurunci-Csacsko E, Kaufmann M, Strebhardt K (2007) Rational combinations of siRNAs targeting Plk1 with breast cancer drugs. Oncogene 26:5793-5807. doi: 10.1038/sj.onc.1210355
207. Spankuch-Schmitt B, Bereiter-Hahn J, Kaufmann M, Strebhardt K (2002) Effect of RNA silencing of Polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J Natl Cancer Inst 94:1863-1877
208. Steegmaier M, Hoffmann M, Baum A et al (2007) BI 2536, a potent and selective inhibitor of Polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 17:316-322. doi: 10.1016/j.cub.2006.12.037
209. Stevens FE, Beamish H, Warrener R, Gabrielli B (2008) Histone deacetylase inhibitors induce mitotic slippage. Oncogene 27:1345-1354. doi: 10.1038/sj.onc.1210779
210. Stolz A, Vogel C, Schneider V, Ertych N, Kienitz A, Yu H, Bastians H (2009) Pharmacologic abrogation of the mitotic spindle checkpoint by an indolocarbazole discovered by cellular screening efficiently kills cancer cells. Cancer Res 69:3874-3883. doi: 10.1158/0008-5472.CAN-08-3597
211. Strebhardt K, Ullrich A (2006) Targeting Polo-like kinase 1 for cancer therapy. Nat Rev Cancer 6:321-330. doi: 10.1038/nrc1841
212. Stucke VM, Sillje HH, Arnaud L, Nigg EA (2002) Human Mps1 kinase is required for the spindle assembly checkpoint but not for centrosome duplication. EMBO J 21:1723-1732. doi: 10.1093/emboj/21.7.1723
213. Sudo T, Nitta M, Saya H, Ueno NT (2004) Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Cancer Res 64:2502-2508
214. Suijkerbuijk SJ, Kops GJ (2008) Preventing aneuploidy: the contribution of mitotic checkpoint proteins. Biochim Biophys Acta 1786:24-31. doi: 10.1016/j.bbcan.2008.04.001
215. Suijkerbuijk SJ, van Osch MH, Bos FL, Hanks S, Rahman N, Kops GJ (2010) Molecular causes for BUBR1 dysfunction in the human cancer predisposition syndrome mosaic variegated aneuploidy. Cancer Res 70:4891-4900. doi: 10.1158/0008-5472.CAN-09-4319
216. Swanton C, Nicke B, Schuett M et al (2009) Chromosomal instability determines taxane response. Proc Natl Acad Sci U S A 106:8671-8676. doi: 10.1073/pnas.0811835106
217. Taddei A, Maison C, Roche D, Almouzni G (2001) Reversible disruption of pericentric heterochromatin and centromere function by inhibiting deacetylases. Nat Cell Biol 3:114-120. doi: 10.1038/35055010
218. Takai N, Hamanaka R, Yoshimatsu J, Miyakawa I (2005) Polo-like kinases (Plks) and cancer. Oncogene 24:287-291. doi: 10.1038/sj.onc.1208272
219. Tang YC, Williams BR, Siegel JJ, Amon A (2011) Identification of aneuploidy-selective antiproliferation compounds. Cell 144:499-512. doi: 10.1016/j.cell.2011.01.017
220. Tanudji M, Shoemaker J, L'Italien L, Russell L, Chin G, Schebye XM (2004) Gene silencing of CENP-E by small interfering RNA in HeLa cells leads to missegregation of chromosomes after a mitotic delay. Mol Biol Cell 15:3771-3781. doi: 10.1091/mbc.E03-07-0482
221. Tao W (2005) The mitotic checkpoint in cancer therapy. Cell Cycle 4:1495-1499
222. Tao Y, Zhang P, Girdler F, Frascogna V, Castedo M, Bourhis J, Kroemer G, Deutsch E (2008) Enhancement of radiation response in p53-deficient cancer cells by the Aurora-B kinase inhibitor AZD1152. Oncogene 27:3244-3255. doi: 10.1038/sj.onc.1210990
223. Tardif KD, Rogers A, Cassiano J et al (2011) Characterization of the cellular and antitumor effects of MPI-0479605, a small-molecule inhibitor of the mitotic kinase Mps1. Mol Cancer Ther 10:2267-2275. doi: 10.1158/1535-7163.MCT- 11-0453
224. Tatsuka M, Katayama H, Ota T, Tanaka T, Odashima S, Suzuki F, Terada Y (1998) Multinuclearity and increased ploidy caused by overexpression of the aurora- and Ipl1-like midbody-associated protein mitotic kinase in human cancer cells. Cancer Res 58:4811-4816
225. Tcherniuk S, van Lis R, Kozielski F, Skoufias DA (2010) Mutations in the human kinesin Eg5 that confer resistance to monastrol and S-trityl-l-cysteine in tumor derived cell lines. Biochem Pharmacol 79:864-872. doi: 10.1016/j.bcp.2009.11.001
226. Terrano DT, Upreti M, Chambers TC (2010) Cyclin-dependent kinase 1-mediated Bcl-xL/Bcl-2 phosphorylation acts as a functional link coupling mitotic arrest and apoptosis. Mol Cell Biol 30:640-656. doi: 10.1128/MCB.00882-09
227. Thompson SL, Compton DA (2008) Examining the link between chromosomal instability and aneuploidy in human cells. J Cell Biol 180:665-672. doi: 10.1083/jcb.200712029
228. Tighe A, Staples O, Taylor S (2008) Mps1 kinase activity restrains anaphase during an unperturbed mitosis and targets Mad2 to kinetochores. J Cell Biol 181:893-901. doi: 10.1083/jcb.200712028
229. Tooley J, Stukenberg PT (2011) The Ndc80 complex: integrating the kinetochore's many movements. Chromosome Res 19:377-391. doi: 10.1007/s10577-010-9180-5
230. Tooley JG, Miller SA, Stukenberg PT (2011) The Ndc80 complex uses a tripartite attachment point to couple microtubule depolymerization to chromosome movement. Mol Biol Cell 22:1217-1226. doi: 10.1091/mbc.E10-07-0626
231. Uetake Y, Sluder G (2010) Prolonged prometaphase blocks daughter cell proliferation despite normal completion of mitosis. Curr Biol 20:1666-1671. doi: 10.1016/j.cub.2010.08.018
232. Vader G, Lens SM (2008) The Aurora kinase family in cell division and cancer. Biochim Biophys Acta 1786:60-72. doi: 10.1016/j.bbcan.2008.07.003
233. Vader G, Medema RH, Lens SM (2006) The chromosomal passenger complex: guiding Aurora-B through mitosis. J Cell Biol 173:833-837. doi: 10.1083/jcb.200604032
234. Vagnarelli P, Earnshaw WC (2004) Chromosomal passengers: the four-dimensional regulation of mitotic events. Chromosoma 113:211-222. doi: 10.1007/s00412-004-0307-3
235. van Engeland M, Kuijpers HJ, Ramaekers FC, Reutelingsperger CP, Schutte B (1997) Plasma membrane alterations and cytoskeletal changes in apoptosis. Exp Cell Res 235:421-430. doi: 10.1006/excr.1997.3738
236. Vogel C, Kienitz A, Hofmann I, Muller R, Bastians H (2004) Crosstalk of the mitotic spindle assembly checkpoint with p53 to prevent polyploidy. Oncogene 23:6845-6853. doi: 10.1038/sj.onc.1207860
237. Vose JM, Friedberg JW, Waller EK, Cheson BD, Juvvigunta V, Fritsch H, Petit C, Munzert G, Younes A (2012) The Plk1 inhibitor BI 2536 in patients with refractory or relapsed non-Hodgkin lymphoma: a phase I, open-label, single dose-escalation study. Leuk Lymphoma. doi: 10.3109/10428194.2012.729833
238. Walsby E, Walsh V, Pepper C, Burnett A, Mills K (2008) Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts. Haematologica 93:662-669. doi: 10.3324/haematol.12148
239. Wang W, Yang Y, Gao Y et al (2009) Structural and mechanistic insights into Mps1 kinase activation. J Cell Mol Med 13:1679-1694. doi: 10.1111/j.1582-4934.2008.00605.x
240. Wang S, Midgley CA, Scaerou F et al (2010) Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors. J Med Chem 53:4367-4378. doi: 10.1021/jm901913s
241. Warrener R, Beamish H, Burgess A, Waterhouse NJ, Giles N, Fairlie D, Gabrielli B (2003) Tumor cell-selective cytotoxicity by targeting cell cycle checkpoints. FASEB J 17:1550-1552. doi: 10.1096/fj.02-1003fje
242. Watanabe N, Sekine T, Takagi M, Iwasaki J, Imamoto N, Kawasaki H, Osada H (2009) Deficiency in chromosome congression by the inhibition of Plk1 polo box domain-dependent recognition. J Biol Chem 284:2344-2353. doi: 10.1074/jbc.M805308200
243. Weaver BA, Cleveland DW (2007) Aneuploidy: instigator and inhibitor of tumorigenesis. Cancer Res 67:10103-10105. doi: 10.1158/0008-5472.CAN-07-2266
244. Weaver BA, Cleveland DW (2008) The aneuploidy paradox in cell growth and tumorigenesis. Cancer Cell 14:431-433. doi: 10.1016/j.ccr.2008.11.011
245. Weaver BA, Bonday ZQ, Putkey FR, Kops GJ, Silk AD, Cleveland DW (2003) Centromere-associated protein-E is essential for the mammalian mitotic checkpoint to prevent aneuploidy due to single chromosome loss. J Cell Biol 162:551-563. doi: 10.1083/jcb.200303167
246. Weaver BA, Silk AD, Montagna C, Verdier-Pinard P, Cleveland DW (2007) Aneuploidy acts both oncogenically and as a tumor suppressor. Cancer Cell 11:25-36. doi: 10.1016/j.ccr.2006.12.003
247. Wei R, Ngo B, Wu G, Lee WH (2011) Phosphorylation of the Ndc80 complex protein, HEC1, by Nek2 kinase modulates chromosome alignment and signaling of the spindle assembly checkpoint. Mol Biol Cell 22:3584-3594. doi: 10.1091/mbc.E11-01-0012
248. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD (2007) Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 7:345-356. doi: 10.1038/nrc2126
249. Welcker M, Clurman BE (2008) FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer 8:83-93. doi: 10.1038/nrc2290
250. Wertz IE, Kusam S, Lam C et al (2011) Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 471:110-114. doi: 10.1038/nature09779
251. Wilkinson RW, Odedra R, Heaton SP et al (2007) AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res 13:3682-3688. doi: 10.1158/1078-0432.CCR-06-2979
252. Wong C, Stearns T (2005) Mammalian cells lack checkpoints for tetraploidy, aberrant centrosome number, and cytokinesis failure. BMC Cell Biol 6:6. doi: 10.1186/1471-2121-6-6
253. Wood KW, Chua P, Sutton D, Jackson JR (2008) Centromere-associated protein E: a motor that puts the brakes on the mitotic checkpoint. Clin Cancer Res 14:7588-7592. doi: 10.1158/1078-0432.CCR-07-4443
254. Wood KW, Lad L, Luo L et al (2010) Antitumor activity of an allosteric inhibitor of centromere-associated protein-E. Proc Natl Acad Sci U S A 107:5839-5844. doi: 10.1073/pnas.0915068107
255. Wu G, Qiu XL, Zhou L, Zhu J, Chamberlin R, Lau J, Chen PL, Lee WH (2008) Small molecule targeting the Hec1/Nek2 mitotic pathway suppresses tumor cell growth in culture and in animal. Cancer Res 68:8393-8399. doi: 10.1158/0008-5472.CAN-08-1915
256. Yamada HY, Gorbsky GJ (2006) Spindle checkpoint function and cellular sensitivity to antimitotic drugs. Mol Cancer Ther 5:2963-2969. doi: 10.1158/1535-7163.MCT-06-0319
257. Yang J, Ikezoe T, Nishioka C et al (2007) AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood 110:2034-2040. doi: 10.1182/blood-2007-02-073700
258. Yang D, Liu H, Goga A, Kim S, Yuneva M, Bishop JM (2010) Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase. Proc Natl Acad Sci U S A 107:13836-13841. doi: 10.1073/pnas.1008366107
259. Yao X, Abrieu A, Zheng Y, Sullivan KF, Cleveland DW (2000) CENP-E forms a link between attachment of spindle microtubules to kinetochores and the mitotic checkpoint. Nat Cell Biol 2:484-491. doi: 10.1038/35019518
260. Yen TJ, Li G, Schaar BT, Szilak I, Cleveland DW (1992) CENP-E is a putative kinetochore motor that accumulates just before mitosis. Nature 359:536-539. doi: 10.1038/359536a0
261. Yoo CB, Jones PA (2006) Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 5:37-50. doi: 10.1038/nrd1930
262. Yvon AM, Wadsworth P, Jordan MA (1999) Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol Biol Cell 10:947-959
263. Zeng WF, Navaratne K, Prayson RA, Weil RJ (2007) Aurora B expression correlates with aggressive behaviour in glioblastoma multiforme. J Clin Pathol 60:218-221. doi: 10.1136/jcp.2006.036806
264. Zhang S, Farag SS (2011) From cell biology to therapy: ENMD-2076 in the treatment of multiple myeloma. Expert Opin Investig Drugs 20:1015-1028. doi: 10.1517/13543784.2011.584869
265. Zhang D, Hirota T, Marumoto T et al (2004) Cre-loxP-controlled periodic Aurora-A overexpression induces mitotic abnormalities and hyperplasia in mammary glands of mouse models. Oncogene 23:8720-8730. doi: 10.1038/sj.onc.1208153
266. Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW, Sahin A, Brinkley BR, Sen S (1998) Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 20:189-193. doi: 10.1038/2496
267. Zich J, Hardwick KG (2010) Getting down to the phosphorylated 'nuts and bolts' of spindle checkpoint signalling. Trends Biochem Sci 35:18-27. doi: 10.1016/j.tibs.2009.09.002